Cedars-Sinai Cancer | Strategic Alliance Partners

Andrew Hendifar, MD, discusses how PEGPH20 improved progression-free survival by 4.9 months in patients with advanced pancreatic cancer with high expression levels of hyaluronan.

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the ongoing phase III ADAPT trial, which examines AGS-003 combined with sunitinib for the treatment of patients with mRCC.

BJ Rimel, MD, discuss the current literature surrounding antiangiogenesis agents in ovarian cancer.

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer(mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.

An improved assay for assessing MRD status in patients with multiple myeloma is contributing to the momentum for using MRD as a surrogate endpoint for survival in clinical trials and as a tool with the potential to help guide therapy choices.

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.